Miyake Y, Kodama T, Yamaguchi K
Growth Factor Division, National Cancer Center Research Institute, Tokyo, Japan.
Cancer Res. 1994 Apr 15;54(8):2136-40.
Gastrin-releasing peptide (GRP) is a specific and an actively secreted product of small cell lung carcinoma (SCLC) cells. Based on this observation, we attempted to develop a new approach for early detection of SCLC and for monitoring therapeutic response in SCLC patients. Recombinant human ProGRP(31-98), a region common to three types of human ProGRP molecules, was synthesized, and a convenient radioimmunoassay system was developed; in this assay, the minimum detectable amount in serum was 10 pM when 0.1 ml of unextracted serum was used. Serum levels of immunoreactive ProGRP(31-98) were measured in 247 normal subjects, 180 patients with nonmalignant pulmonary diseases, 231 patients with non-SCLC, and 140 patients with SCLC. The percentages of subjects with the level greater than 10 pM in normal subjects and patients with nonmalignant pulmonary diseases and with non-SCLC were 1.2, 2.2, and 3.0%, respectively. In contrast, 76% of patients with SCLC had elevated levels; the positive rates in SCLC patients with limited and extensive diseases were 73 and 79%, respectively, indicating that the serum Pro-GRP(31-98) level could serve as a reliable tumor marker in SCLC patients, even at a relatively early stage of this disease. Moreover, changes in the serum ProGRP(31-98) showed excellent correlation with the therapeutic responses in SCLC patients. These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.
胃泌素释放肽（GRP）是一种由小细胞肺癌（SCLC）细胞特异性分泌的活性产物。基于这一观察结果，我们试图开发一种新的方法来早期检测SCLC，并监测SCLC患者的治疗反应。合成了重组人ProGRP（31 - 98），这是三种人ProGRP分子共有的区域，并开发了一种便捷的放射免疫分析系统；在该分析中，当使用0.1 ml未提取的血清时，血清中的最低可检测量为10 pM。检测了247名正常受试者、180名非恶性肺部疾病患者、231名非SCLC患者和140名SCLC患者血清中免疫反应性ProGRP（31 - 98）的水平。正常受试者、非恶性肺部疾病患者和非SCLC患者中水平大于10 pM的受试者百分比分别为1.2%、2.2%和3.0%。相比之下，76%的SCLC患者水平升高；局限性和广泛性疾病的SCLC患者阳性率分别为73%和79%，这表明血清Pro - GRP（31 - 98）水平即使在该疾病相对早期阶段也可作为SCLC患者可靠的肿瘤标志物。此外，血清ProGRP（31 - 98）的变化与SCLC患者的治疗反应显示出极好的相关性。这些结果表明，测定血清ProGRP（31 - 98）水平在SCLC患者的诊断和治疗中起着重要作用。
